Explorez tous les épisodes du podcast Psychopharmacology and Psychiatry Updates
| Titre | Date | Durée | |
|---|---|---|---|
| SSRIs and Psychedelics: Drug Interactions | 03 oct. 2025 | 00:11:14 | |
In this episode, we explore the complex drug-drug interactions between psychedelics and psychiatric medications. Do SSRIs really blunt psychedelic effects, or is this just clinical folklore? We'll examine surprising new research and discuss potentially dangerous combinations every psychiatrist should know. Faculty: Franklin King, M.D. | |||
| Standard vs. High Doses: Rethinking Bipolar Maintenance Treatment | 28 sept. 2025 | 00:14:06 | |
In this episode, we challenge the conventional wisdom of “what gets them well keeps them well” by exploring groundbreaking Finnish research on bipolar disorder medication dosing. Does maintaining patients on high doses actually improve long-term outcomes, or could standard doses be the optimal strategy for relapse prevention? Faculty: Kristin Raj, M.D. | |||
| Psychedelics and Brain Networks | 23 sept. 2025 | 00:14:11 | |
In this episode, we explore how psychedelics like psilocybin disrupt the brain's default mode network, creating windows of neuroplasticity that correlate with mystical experiences and therapeutic breakthroughs in treatment-resistant depression, anxiety, and addiction. Faculty: Franklin King, M.D. | |||
| LAIs vs Oral Antipsychotics: Mortality Data and Clinical Impact | 18 sept. 2025 | 00:16:33 | |
In this episode, we explore groundbreaking research showing how long-acting injectable antipsychotics can literally save lives in schizophrenia treatment. Could choosing the right medication delivery method be the difference between a patient thriving or facing premature death by 15-20 years? Faculty: Oliver Freudenreich, M.D. | |||
| The Science Behind Psychedelic Therapy | 13 sept. 2025 | 00:15:55 | |
In this episode, we explore the fascinating mechanisms behind psychedelic drugs in psychiatry, examining how substances like psilocybin and LSD work through 5-HT2A receptors to promote neuroplasticity. What if these compounds are hijacking an ancient stress response system designed to help us rapidly adapt to survive? Faculty: Franklin King, M.D. | |||
| Which Antidepressant Causes the Most Weight Gain? | 08 sept. 2025 | 00:12:11 | |
In this episode, we explore groundbreaking research comparing weight gain across eight common antidepressants. Using data from 183,000 patients, this study finally provides concrete numbers to answer the question patients ask most: How much weight will I gain on this medication? Faculty: Paul Zarkowski, M.D. | |||
| Lisdexamfetamine for Binge Eating Disorder | 03 sept. 2025 | 00:12:14 | |
In this episode, we explore lisdexamfetamine as the first FDA-approved medication for binge eating disorder. Can one medication effectively treat both ADHD and binge eating simultaneously? We examine the evidence, duration of treatment, and strategies for addressing patient ambivalence in eating disorder pharmacotherapy. Faculty: Scott Crow, M.D. | |||
| Beyond Weight Loss: GLP-1 Agonists and Alcohol Use Disorder | 29 août 2025 | 00:11:27 | |
In this episode, we explore groundbreaking Swedish research on GLP-1 receptor agonists as a potential new treatment for alcohol use disorder. Could diabetes medications like semaglutide revolutionize addiction treatment where traditional therapies have fallen short? Faculty: David Gorelick, M.D. | |||
| Antidepressants vs. Anticonvulsants for Binge Eating | 24 août 2025 | 00:11:26 | |
In this episode, we explore pharmacotherapy for binge eating disorder, examining how antidepressants, anticonvulsants, and emerging treatments target different patient goals. Should your treatment focus on stopping binge episodes or achieving weight loss? We discuss evidence-based approaches to align medication choices with patient priorities for optimal outcomes. Faculty: Scott Crow, M.D. | |||
| Lithium Levels: Finding the Right Therapeutic Target | 19 août 2025 | 00:11:19 | |
In this episode, we explore the confusing world of lithium therapeutic levels with Dr. Paul Zarkowski. Why do different labs recommend different ranges for the same medication? We examine expert consensus on optimal dosing strategies for both acute treatment and maintenance therapy in bipolar disorder. Faculty: Paul Zarkowski, M.D. | |||
| Antidepressants Beyond Depression: Applications in Bulimia Nervosa | 14 août 2025 | 00:09:28 | |
In this episode, we explore evidence-based pharmacotherapy for bulimia nervosa, including why higher doses of SSRIs work better than standard dosing, which medications to avoid completely, and how antidepressants can be effective even without depression being present. Why does fluoxetine require 60 mg daily for optimal results? Faculty: Scott Crow M.D. | |||
| Metformin and Antipsychotic-Induced Weight Gain: An Evidence-Based Solution | 09 août 2025 | 00:12:10 | |
In this episode, we explore groundbreaking research on managing antipsychotic-induced weight gain through a comprehensive network meta-analysis. Could the combination of low-dose metformin and lifestyle modifications be the game-changer that helps patients maintain both mental stability and physical health? Faculty: Scott Beach, M.D. | |||
| Monthly Injections, Long-Term Recovery: Naltrexone for OUD | 04 août 2025 | 00:08:17 | |
In this episode, we explore extended-release naltrexone for opioid use disorder, examining its unique role as a pure antagonist in patients who require safety-sensitive careers. How do we successfully navigate the challenging initiation period when patients must be opioid-free for a week?
| |||
| Antipsychotics and Aspiration Risk | 30 juil. 2025 | 00:12:03 | |
In this episode, we explore the surprising link between antipsychotic medications and pneumonia risk. Did you know that pneumonia is the fourth leading cause of death in schizophrenia patients, and certain medications increase this risk in unexpected ways? Faculty: Scott Beach, M.D. | |||
| Buprenorphine, Methadone, and Naltrexone: Helping Patients with OUD Decide | 25 juil. 2025 | 00:11:10 | |
In this episode, we explore how to choose between methadone, buprenorphine, and naltrexone for opioid use disorder treatment. With over 100,000 overdose deaths annually, how do we match the right medication to save each patient's life? Faculty: Smita Das, M.D.
| |||
| Managing OUD with Buprenorphine: Clinical Pearls | 20 juil. 2025 | 00:12:04 | |
In this episode, we explore buprenorphine management for opioid use disorder, covering induction protocols, dosing strategies, and long-term maintenance. Why do patients need to be in withdrawal before starting this life-saving medication, and how can we make this challenging process more manageable? Faculty: Smita Das, M.D. | |||
| Valproate Weight Gain: Do Lower Doses Help? | 15 juil. 2025 | 00:09:18 | |
In this episode, we explore groundbreaking research on valproate's dose-dependent weight gain effects. Could prescribing lower doses be the key to maintaining therapeutic benefits while minimizing one of psychiatry's most challenging side effects? Dr. Paul Zarkowski reveals surprising findings that could transform your valproate prescribing approach. Faculty: Paul Zarkowski, M.D. | |||
| Methadone for Opioid Use Disorder | 10 juil. 2025 | 00:09:27 | |
In this episode, we explore methadone maintenance therapy for opioid use disorder, covering dosing strategies, recent regulatory changes, and safety considerations. Why do so many patients fail on methadone despite its proven effectiveness, and how can proper dosing make the difference between recovery and relapse? Faculty: Smita Das, M.D. | |||
| Clozapine and Compulsions: New Research On An Old Side Effect | 05 juil. 2025 | 00:13:48 | |
In this episode, we explore the puzzling connection between clozapine and obsessive-compulsive symptoms in schizophrenia patients. Does this wonder drug actually cause OCD, or are we missing a deeper story about how protective behaviors transform into compulsive habits? Faculty: Oliver Freudenreich, M.D. | |||
| Naltrexone vs. Topiramate: FDA-Approved vs. Off-Label Options for MAUD | 30 juin 2025 | 00:10:07 | |
In this episode, we explore groundbreaking head-to-head research comparing topiramate and naltrexone for alcohol use disorder, revealing surprising equivalence in effectiveness. Could the off-label option actually be as good as our FDA-approved standard for treating problematic drinking? Faculty: David Gorelick, M.D. | |||
| Beyond Tapering: Supporting Patients Through Benzodiazepine Discontinuation | 25 juin 2025 | 00:13:36 | |
In this episode, we discuss the critical challenges of benzodiazepine discontinuation, exploring Benzodiazepine-Induced Neurological Dysfunction (BIND) and effective support strategies for patients experiencing protracted withdrawal. What can clinicians do when over 50% of patients report finding more help from online forums than from medical professionals? Faculty: Alexis Ritvo, M.D. | |||
| Beyond Blood Counts: Clozapine, Bowel Obstruction, and Pneumonia | 20 juin 2025 | 00:12:48 | |
In this episode, we explore the potentially fatal side effects of clozapine that often receive less attention than agranulocytosis: bowel obstruction and pneumonia. Could your vigilant monitoring of blood counts be overshadowing equally dangerous risks? Faculty: Oliver Freudenreich, M.D. | |||
| Demystifying Benzodiazepine Deprescribing: Smart Approaches to Tapering | 15 juin 2025 | 00:15:02 | |
In this episode, we discuss evidence-based strategies for safely tapering patients off benzodiazepines, including cut-and-hold and microtapering techniques. What's the best approach when commercial dosage forms limit gradual reductions? Faculty: Alexis Ritvo | |||
| Lithium: Implications for Bone Health | 10 juin 2025 | 00:10:27 | |
In this episode, we explore lithium's surprising positive effect on bone mineral density in patients with bipolar disorder. Could the medication many psychiatrists use as a mood stabilizer also be protecting patients from osteoporosis? Faculty: Paul Zarkowski, M.D. | |||
| Tapering with Care: Benzodiazepine Discontinuation | 05 juin 2025 | 00:15:33 | |
In this episode, we explore evidence-based strategies for successful benzodiazepine tapering with addiction psychiatrist Dr. Alexis Ritvo. How can clinicians minimize withdrawal effects while supporting patients through this challenging process? Faculty: Alexis Ritvo, M.D. | |||
| Dementia Risk and Vitamin D | 31 mai 2025 | 00:10:51 | |
In this episode, we explore compelling evidence from the UK Biobank showing how vitamin D deficiency may increase dementia risk by up to 25%. Could this affordable supplement be an essential piece of your brain health strategy? Faculty: Scott Beach, M.D.
| |||
| Beyond Benzos: Strategies for Successful Deprescribing | 26 mai 2025 | 00:13:41 | |
In this episode, we explore the complex process of benzodiazepine deprescribing, examining when and how to help patients reduce or discontinue these medications. How can clinicians balance the benefits of deprescription against the challenges of withdrawal? Faculty: Alexis Ritvo, M.D. | |||
| Motherhood and Medication: LAIs for Women with Schizophrenia | 21 mai 2025 | 00:12:06 | |
In this episode, we explore the unique considerations for using long-acting injectable antipsychotics in women with schizophrenia. How might hormonal fluctuations throughout a woman's life impact treatment decisions for schizophrenia? Faculty: Oliver Freudenreich, M.D. | |||
| Benzodiazepines in High-Risk Populations | 16 mai 2025 | 00:09:30 | |
In this episode, we explore the challenges and current guidelines for benzodiazepine use in pregnancy, breastfeeding, and adolescence. When is it appropriate to continue benzodiazepines during pregnancy, and what alternatives should clinicians consider? Faculty: Alexis Ritvo, M.D. | |||
| Benzodiazepines: Understanding Physical Dependence vs. Addiction | 11 mai 2025 | 00:12:27 | |
In this episode, we explore benzodiazepine use disorder, distinguishing between physical dependence and addiction while examining practical strategies for safe prescribing. Did you know only 1.5% of benzodiazepine users actually develop a use disorder? Faculty: Alexis Ritvo, M.D. | |||
| Beyond Metformin: Probiotics and Antipsychotic Weight Gain | 06 mai 2025 | 00:12:46 | |
In this episode, we explore the potential role of the probiotic Akkermansia muciniphila in managing olanzapine-induced weight gain. Could this tiny gut bacterium be the key to maintaining metabolic health while on antipsychotics? Faculty: Oliver Freudenreich, M.D. | |||
| What Every Clinician Should Know About the Risks of Benzodiazepines | 01 mai 2025 | 00:09:48 | |
In this episode, we explore the dangerous risks of benzodiazepine use, focusing on the potentially lethal combination with opioids, cognitive impairment, increased accident risk, and fall hazards. Did you know that benzodiazepines combined with opioids increase overdose risk fivefold in the first 90 days? Faculty: Alexis Ritvo, M.D. | |||
| Making an Exit Plan: Navigating Antidepressant Discontinuation | 26 avr. 2025 | 00:11:31 | |
In this episode, we explore the latest research on antidepressant discontinuation symptoms, revealing that about 14% of patients experience these effects when stopping medication. Which antidepressants are most likely to cause these "brain zaps" and other withdrawal symptoms? Faculty: Scott Beach, M.D. | |||
| Clinical Pearls for Selecting the Right Benzodiazepine | 21 avr. 2025 | 00:11:54 | |
In this episode, we discuss the appropriate use of benzodiazepines, focusing on evidence-based indications and optimal medication selection. Did you know that alprazolam has unique properties that make it more addictive than other benzodiazepines? Faculty: Alexis Ritvo, M.D. | |||
| TMS for Depression: From Clinical Trials to Results | 16 avr. 2025 | 00:16:27 | |
In this episode, we explore the evidence behind Transcranial Magnetic Stimulation (TMS) for depression, from early clinical trials to real-world effectiveness. What makes some patients respond better to TMS than others? We discuss response rates, treatment protocols, and the exciting development of faster treatment options. Faculty: Simon Kung, M.D. | |||
| A Guide to Selecting TMS Candidates | 11 avr. 2025 | 00:13:35 | |
In this episode, we explore the crucial aspects of patient selection for Transcranial Magnetic Stimulation (TMS) in treating depression. We discuss insurance criteria, contraindications, and practical considerations. Did you know that while TMS was FDA-approved in 2008, it wasn't widely accessible until Medicare began covering it in 2014? Faculty: Simon Kung, M.D. | |||
| Rethinking Clozapine Monitoring: 22 Years of Data | 06 avr. 2025 | 00:13:07 | |
In this episode, we explore a landmark Finnish study examining the long-term risk of agranulocytosis in patients taking clozapine. The research followed 62,000 patients over 22 years, providing crucial data about this rare but serious side effect. Could these findings change how we approach clozapine prescribing and monitoring requirements? Faculty: Oliver Freudenreich, M.D. | |||
| Understanding TMS in OCD: Evidence and Practice | 01 avr. 2025 | 00:08:32 | |
In this episode, we explore Transcranial Magnetic Stimulation (TMS) as a treatment option for Obsessive-Compulsive Disorder (OCD). We discuss the FDA-approved devices, unique protocols, and why patients need their anxiety triggered before each session. Did you know TMS for OCD targets a completely different brain region than TMS for depression? Faculty: Simon Kung, M.D. | |||
| Breaking Down the TRAILBLAZER-ALZ 2 Trial | 27 mars 2025 | 00:10:27 | |
In this episode, we explore donanemab, a groundbreaking monoclonal antibody treatment for Alzheimer's disease. We discuss its efficacy in reducing beta-amyloid plaques, unique treatment duration protocol, and safety considerations. Could this time-limited treatment approach revolutionize how we manage Alzheimer's progression? Faculty: Scott Beach, M.D. | |||
| Long-term Benzo Use: What The Data Really Show | 22 mars 2025 | 00:10:58 | |
In this episode, we explore a groundbreaking Danish registry study that challenges common beliefs about long-term benzodiazepine use and dose escalation patterns. Are our concerns about inevitable tolerance and dependence justified? The study's findings might surprise you and reshape prescribing practices. Faculty: Scott Beach, M.D. | |||
| Navigating TMS Side Effects: A Practical Guide | 17 mars 2025 | 00:08:05 | |
In this episode, we explore the side effects and safety considerations of Transcranial Magnetic Stimulation (TMS) therapy in psychiatry. Did you know that despite common concerns, fewer than 2% of patients discontinue TMS due to discomfort? We'll discuss everything from common side effects to practical management strategies. Faculty: Simon Kung, M.D. | |||
| SSRIs and Anticoagulants: Navigating Bleeding Risk | 12 mars 2025 | 00:11:06 | |
In this episode, we explore the crucial interaction between SSRIs and oral anticoagulants, examining a groundbreaking 23-year study of over 330,000 patients. Does combining these medications significantly increase bleeding risk, and if so, how can we safely manage patients who need both treatments? Faculty: Scott Beach, M.D. | |||
| Lamotrigine and the Heart: What You Need to Know | 07 mars 2025 | 00:07:38 | |
In this episode, we explore the safe use and monitoring of lamotrigine, focusing on cardiac risks and when EKG monitoring is necessary. Did you know that reducing lamotrigine dose doesn't actually mitigate cardiac risks but could increase the risk of psychiatric destabilization? Faculty: Scott Beach, M.D. | |||
| After the Last Dose: Understanding Antipsychotic Discontinuation | 02 mars 2025 | 00:11:27 | |
In this episode, we explore the often-overlooked phenomenon of antipsychotic withdrawal, examining new findings from the world's largest drug safety database. Could some cases of apparent psychotic relapse actually be withdrawal symptoms in disguise? We discuss common withdrawal effects, risk factors, and evidence-based strategies for safe medication discontinuation. Faculty: Oliver Freudenreich, M.D. | |||
| Understanding Lamotrigine's Cardiac Effects | 25 févr. 2025 | 00:07:38 | |
In this episode, we explore lamotrigine's cardiac side effects, focusing on QTc prolongation and QRS widening. How concerned should psychiatrists be about the FDA warning regarding lamotrigine's cardiac effects? We examine the evidence behind these concerns and discuss practical implications for clinical practice. Faculty: Scott Beach, M.D. | |||
| Rethinking Falls: Are Sleep Medications Really to Blame? | 20 févr. 2025 | 00:12:09 | |
In this episode, we examine a groundbreaking Danish study that challenges the conventional belief that sedative medications increase fall risk in older adults. Could untreated insomnia, rather than the medications used to treat it, be the real culprit behind falls in elderly patients? Faculty: Scott Beach, M.D. | |||
| Navigating Lamotrigine's Side Effects | 15 févr. 2025 | 00:10:42 | |
In this episode, we explore lamotrigine's side effects and special considerations, particularly focusing on identifying dangerous skin reactions, pregnancy considerations, and overdose risks. Did you know that Asian populations may require special genetic screening before starting lamotrigine due to increased skin reaction risks? Faculty: Scott Beach, M.D. | |||
| Iloperidone in Bipolar Disorder: A New Treatment Option? | 10 févr. 2025 | 00:09:23 | |
In this episode, we explore the efficacy and safety of iloperidone in treating bipolar disorder, examining new phase 3 trial data that reveals both promising results for mania symptoms and important considerations about side effects. Can this antipsychotic's favorable EPS profile outweigh its metabolic risks? Faculty: Paul Zarkowski, M.D. | |||
| Lamotrigine: Pearls for Prescribing | 05 févr. 2025 | 00:08:44 | |
In this episode, we explore the vital aspects of prescribing lamotrigine, from its mechanisms to titration schedules. Did you know that birth control pills can cut lamotrigine levels in half within just one week? Understanding these interactions is crucial for safe and effective treatment. Faculty: Scott Beach, M.D. | |||
| Beyond Benzos: New Frontiers in Agitation Management | 31 janv. 2025 | 00:10:19 | |
In this episode, we explore the pharmacological management of agitation in emergency settings, focusing on benzodiazepines and the novel medication dexmedetomidine. Did you know there's now a sublingual option that works through an entirely different mechanism than traditional anti-agitation medications? Faculty: Scott Zeller, M.D. | |||